There has been significant use of digital tools in specialty pharmacy during the COVID-19 pandemic, but it remains to be seen if that move will remain permanent in addition to other offerings, in a less acute setting of care, said Lance Grady, market access practice director, Avalere Health.
There has been significant use of digital tools in specialty pharmacy during the COVID-19 pandemic, but it remains to be seen if that move will remain permanent in addition to other offerings, in a less acute setting of care, said Lance Grady, market access practice director, Avalere Health.
Transcript
How are the digital support tools of the pandemic helping to improve specialty prescription fulfillment and therapy?
We're seeing significant innovation on the pharmacy switch, whether that be through the benefit or above the benefit, we know that e-pharmacy solutions or pharmacy solutions that are on the switch are proliferating. I think the question is going to be to the plans and PBMs [pharmacy benefit managers] and payers as to, does that become flexibility for their members? And does that flexibility for their members move towards their own sort of PBM-owned or plan-coordinated or plan-contracted specialty pharmacy to also offer those types of innovations?
That’s the open question that we still don't know yet. Meaning, does, does a large PBM-owned specialty pharmacy innovate with digital solutions and e-solutions as a supplement to their already rather proven sort of call center with education nurses with benefits specialists and counselors and coordinators and, of course, pharmacists. So, I think that is the still the unanswered question. Do we see the innovation stay sort of in the periphery or do we see it move to large or mid-size specialty pharmacy as a part of a comprehensive offering for plans and our plan members?
Early Detection Strategies for Interstitial Lung Disease in Rheumatology: Janet Pope, MD, MPH
August 11th 2025Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic sclerosis, rheumatoid arthritis, and other connective tissue diseases.
Read More
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More